Climb Bio annual stock-based compensation
2020
2021
2022
2023
2024
2025
Climb Bio Stock-Based Compensation Growth & History (CLYM)
Climb Bio's stock-based compensation was $8.1M for fiscal 2025.
View full Climb Bio company overviewClimb Bio annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.1M | $2.5M | +44.93% |
| 2024 | 2024-12-31 | $5.6M | −$7.2M | −56.61% |
| 2023 | 2023-12-31 | $12.8M | $5.8M | +83.18% |
| 2022 | 2022-12-31 | $7.0M | $3.3M | +87.08% |
| 2021 | 2021-12-31 | $3.7M | $3.0M | +428.57% |
| 2020 | 2020-12-31 | $707,000 | — | — |
Climb Bio quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.5M | $468,000 | +46.20% |
| Q1 2026 | 2026-03-31 | $1.6M | −$417,000 | −20.62% |
| Q4 2025 | 2025-12-31 | $1.0M | −$615,000 | −37.09% |
| Q3 2025 | 2025-09-30 | $4.0M | $1.1M | +36.07% |
| Q2 2025 | 2025-06-30 | $1.0M | $501,000 | +97.85% |
| Q1 2025 | 2025-03-31 | $2.0M | $1.6M | +334.84% |
| Q4 2024 | 2024-12-31 | $1.7M | $456,000 | +37.94% |
| Q3 2024 | 2024-09-30 | $2.9M | $2.3M | +345.43% |
| Q2 2024 | 2024-06-30 | $512,000 | −$265,000 | −34.11% |
| Q1 2024 | 2024-03-31 | $465,000 | −$9.7M | −95.43% |
| Q4 2023 | 2023-12-31 | $1.2M | −$693,000 | −36.57% |
| Q3 2023 | 2023-09-30 | $656,000 | −$1.1M | −63.21% |
| Q2 2023 | 2023-06-30 | $777,000 | −$995,000 | −56.15% |
| Q1 2023 | 2023-03-31 | $10.2M | $8.6M | +560.03% |
| Q4 2022 | 2022-12-31 | $1.9M | $741,000 | +64.21% |
| Q3 2022 | 2022-09-30 | $1.8M | $547,000 | +44.26% |
| Q2 2022 | 2022-06-30 | $1.8M | $722,000 | +68.76% |
| Q1 2022 | 2022-03-31 | $1.5M | $1.2M | +418.86% |
| Q4 2021 | 2021-12-31 | $1.2M | — | — |
| Q3 2021 | 2021-09-30 | $1.2M | $1.2M | +2422.45% |
| Q2 2021 | 2021-06-30 | $1.1M | $999,000 | +1958.82% |
| Q1 2021 | 2021-03-31 | $297,000 | — | — |
| Q3 2020 | 2020-09-30 | $49,000 | — | — |
| Q2 2020 | 2020-06-30 | $51,000 | — | — |
Climb Bio stock-based compensation trends
Over the last five fiscal years, Climb Bio's stock-based compensation increased from $707,000 to $8.1M, a change of $7.3M. The latest reported quarter, Q2 2026, shows $1.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Climb Bio source filings ↗